Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25. [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 416. 2016 Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Antineoplastic Agents; Humans Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32016001052 Date abstract record published 19/10/2016 |